Abiopharma

🔍 Torley Helen (Director)

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Report Date: 2026-02-09

Detailed Transactions and Holdings:

• Acquired 53,847 shares of Option to Purchase Common Stock at $80.48 per share (Derivative)
  Date: 2026-02-09 | Code: A | Expires: 2036-02-09 | Exercise: 2027-02-09 | equity_swap_involved: 0 | shares_owned_after: 53,847.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 50,013 shares of Restricted Stock Units (Derivative)
  Date: 2026-02-09 | Code: A | Exercise: 2027-02-09 | equity_swap_involved: 0 | shares_owned_after: 50,013.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Acquired 19,807 shares of Performance Stock Units (Derivative)
  Date: 2026-02-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 51,171.00 | transaction_form_type: 4 | Footnotes: F3, F3
• Acquired 24,985 shares of Performance Stock Units (Derivative)
  Date: 2026-02-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 144,400.00 | transaction_form_type: 4 | Footnotes: F4, F4
• Acquired 92,714 shares of Performance Stock Units (Derivative)
  Date: 2026-02-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 92,714.00 | transaction_form_type: 4 | Footnotes: F5, F5

Footnotes:

• F1: This option vests one-fourth on such date and then 1/48th monthly thereafter.
• F2: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
• F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
• F4: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
• F5: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.